Targeting the Bcl-2 family in cancer therapy.
The targeting of anti-apoptotic members of the Bcl-2 family of proteins, especially Bcl-2, is the focus of efforts to modulate the intrinsic pathway of apoptosis and effect tumor death. Current understanding of the role of Bcl-2 family proteins and strategies and recent developments in drug inhibitors of these proteins, particularly antisense oligonucleotides and targeted small molecules, are reviewed.
Papadopoulos
Kyriakos
K
Institute for Drug Development, Cancer Therapy and Research Center, and Division of Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, TX, USA. kpapadop@idd.org
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000187:drug effects*; D051028:bcl-2-Associated X Protein / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D051028:bcl-2-Associated X Protein